Skip to main content

Advertisement

Log in

Lipid-Lowering Agents in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Human Studies

Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease which refers to the presence of hepatic steatosis without significant intake of alcohol. NAFLD is an asymptomatic disease that can progress to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma. NAFLD is currently the most common cause of incidental abnormal liver tests and elevated serum liver enzyme activities in the developed world. Obesity, diabetes, and other components of the metabolic syndrome are frequently associated with the NAFLD. The treatment of NAFLD focuses on life-style modifications. Statins, fibrates, and other lipid-lowering agents have been proposed as effective lipid-lowering treatments in patients with NAFLD/NASH. However, clinicians are concerned that hyperlipidemic patients with NAFLD/NASH who are treated with statins could develop transaminitis. We assessed the efficacy and safety of lipid-lowering agents for NAFLD/NASH by reviewing reports of human studies including pilot, prospective, preliminary, and post hoc analysis studies on online databases during the period of 1980 to December 2012. The results of studies provide compelling evidence that lipid-lowering agents are safe and efficacious in patients with NAFLD/NASH and that some of these agents can induce a reduction in the extent of the hepatic steatosis. Well-designed randomized controlled studies of adequate size and duration with histological endpoints are needed in order to establish a suitable lipid-lowering treatment for hyperlipidemic patients with NAFLD/NASH, and for nonhyperlipidemic patients with NAFLD/NASH with a high risk for cardiovascular disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134–140.

    Article  PubMed  Google Scholar 

  2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–438.

    PubMed  CAS  Google Scholar 

  3. Angulo P. Nonalcoholic fatty liver diseases. N Eng J Med. 2002;346:1221–1231.

    Article  CAS  Google Scholar 

  4. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–923.

    Article  PubMed  Google Scholar 

  5. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and metabolic syndrome. Curr Opin Lipidol. 2005;16:421–427.

    Article  PubMed  CAS  Google Scholar 

  6. Kral JG, Schaffner F, Pierson RN Jr, Wang J. Body fat topography as an independent predictor of fatty liver. Metabolism. 1993;42:548–551.

    Article  PubMed  CAS  Google Scholar 

  7. Azzout-Marniche D, Bécard D, Guichard C, Foretz M, Ferré P, Foufelle F. Insulin effects on sterol regulatory-element-binding protein-1c (SREBP-1c) transcriptional activity in rat hepatocytes. Biochem J. 2000;350:389–393.

    Article  PubMed  CAS  Google Scholar 

  8. Day CP, James OF. Steatohepatitis: a tale of two “hits.” Gastroenterology. 1998;114:842–845.

    Article  PubMed  CAS  Google Scholar 

  9. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 2002;35:898–904.

    Article  PubMed  CAS  Google Scholar 

  10. Assy N, Kaita K, Mymin D, Levy C, Roser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 2000;45:1929–1934.

    Article  PubMed  CAS  Google Scholar 

  11. Solderberg C, Stal P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;2:595–602.

    Article  Google Scholar 

  12. Nseir W, Shalata A, Marmor A, Assy N. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci. 2011;56:3439–3449.

    Article  PubMed  CAS  Google Scholar 

  13. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation. 1994;89:1333–1445.

    Article  Google Scholar 

  14. Tandra S, Vuppalanchi R. Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med. 2009;11:272–273.

    Article  PubMed  Google Scholar 

  15. Charles EC, Olson KL, Sandhoff BG, McClure DL, Merenich JA. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med. 2005;118:618–624.

    Google Scholar 

  16. Adiels M, Taskinen MR, Packard C, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006;49:755–765.

    Article  PubMed  CAS  Google Scholar 

  17. Nseir W, Nassar F, Assy N. Soft drinks consumption and nonalcoholic fatty liver disease. World J Gastroenterol. 2010;16:2579–2588.

    Article  PubMed  CAS  Google Scholar 

  18. Abid A, Taha O, Nseir W, Farah R, Grosovski M, Assy N. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol. 2009;51:918–924.

    Article  PubMed  CAS  Google Scholar 

  19. Leclercq IA, Horsmans Y. Nonalcoholic fatty liver disease: the potential role of nutritional management. Curr Opin Clin Nutr Metab Care. 2008;11:766–773.

    Article  PubMed  CAS  Google Scholar 

  20. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21:697–738.

    Article  PubMed  CAS  Google Scholar 

  21. Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk. 2000;7:325–331.

    PubMed  CAS  Google Scholar 

  22. Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2006;91:4753–4761.

    Article  PubMed  CAS  Google Scholar 

  23. Mazzone T, Foster D, Chait A. In vivo stimulation of low-density lipoprotein degradation by insulin. Diabetes. 1984;33:333–338.

    Article  PubMed  CAS  Google Scholar 

  24. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7–22.

    Article  Google Scholar 

  25. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmol Sci. 2002;23:482–486.

    Article  CAS  Google Scholar 

  26. Nseir W, Khateeb J, Tatour I, Haiek S, Samara M, Assy N. Long-term statin therapy affects the severity of chronic gastritis. Helicobacter. 2010;15:510–515.

    Article  PubMed  CAS  Google Scholar 

  27. Nseir W, Mograbi J, Abu-Elheja O, Bishara J, Assy N. The impact of prior long-term versus short-term statin use on the mortality of bacteraemic patients. Infection. 2012;40:41–48.

    Google Scholar 

  28. Halcox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation. 2004;109:II42–II48.

    Article  PubMed  Google Scholar 

  29. Abel T, Feher J, Dinya H, Eldin MG, Kovacs A. Safety and efficacy of combined ezetemibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Med Sci Monit. 2009;15:MS6–MS11.

    PubMed  CAS  Google Scholar 

  30. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol. 2009;43:990–994.

    Article  PubMed  CAS  Google Scholar 

  31. Mihaila RG, Nedelcu L, Fratila O, Rezi EC, Domnariu C, Deac M. Effects of lovastatin and pentoxyphyllin in nonalcoholic steatohepatitis. Hepatogastroenterology. 2009;56:1117–1121.

    PubMed  CAS  Google Scholar 

  32. Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis. 2004;174:193–196.

    Article  PubMed  CAS  Google Scholar 

  33. Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007;46:1453–1463.

    Article  PubMed  CAS  Google Scholar 

  34. Hyogo H, Ikegami T, Tokushige K, et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study. Hepatol Res. 2011;41:1057–1065.

    Article  PubMed  CAS  Google Scholar 

  35. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, García-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemidia, non-alcoholic fatty liver patients. Aliment Pharmacol Ther. 2006;23:1643–1647.

    Article  PubMed  CAS  Google Scholar 

  36. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver test in the Greek atorvastatin and coronary heart disease evaluation (GREACE) study: a post hoc analysis. Lancet. 2010;376:1916–1922.

    Article  PubMed  CAS  Google Scholar 

  37. Kiyici M, Gulten M, Gurel S, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol. 2003;17:713–718.

    PubMed  Google Scholar 

  38. Athyros VG, Mikhaildis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomized study. Cur Med Res Opin. 2006;22:873–883.

    Article  CAS  Google Scholar 

  39. Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of preliminary study. J Gastrointestin Liver Dis. 2007;16:39–46.

    PubMed  Google Scholar 

  40. Kimura Y, Hyogo H, Yamagishi S, et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol. 2010;45:750–757.

    Article  PubMed  CAS  Google Scholar 

  41. Samy W, Hassanian MA. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin. Arab J Gastroenterol. 2011;12:80–85.

    Article  PubMed  CAS  Google Scholar 

  42. Antonopoulos S, Mikros S, Mylonopoulou M, Kokkoris S, Giannoulis G. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis. 2006;184:233–234.

    Article  PubMed  CAS  Google Scholar 

  43. Grundy SM, Ahrens EH Jr, Salen G, Schreibman PH, Nestel PJ. Mechanisms of action of clofibrate on cholesterol metabolism patients with hyperlipidemia. J Lipid Res. 1972;13:531–551.

    PubMed  CAS  Google Scholar 

  44. Laurin J, Lindor KD, Crippin JS, et al. Urseodeoxycholic acid or clofibrate in the treatment of non-alcoholic-induced steatohepatitis: a pilot study. Hepatology. 1996;23:1464–1467.

    Article  PubMed  CAS  Google Scholar 

  45. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol. 1999;31:384.

    Article  PubMed  CAS  Google Scholar 

  46. Fernandez-Miranda C, Perez-Carreras M, Colina F, Lopez-Alonso G, Vargas C, Solis-Herruzo JA. A pilot trial of fenofibrate for the treatment of non-alcoholic liver disease. Dig Liver Dis. 2008;40:200–205.

    Article  PubMed  CAS  Google Scholar 

  47. McCormack PL, Keating GM. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidemia. Drugs. 2005;65:2719–2740.

    Article  PubMed  CAS  Google Scholar 

  48. Paolini JF, Bays HE, Ballantyne CM, et al. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin. 2008;26:547–560.

    Article  PubMed  Google Scholar 

  49. Fabbrini E, Mohammed BS, Korenblat KM, et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with non-alcoholic fatty liver disease. J Clin Endocrinol Metab. 2010;95:2727–2735.

    Article  PubMed  CAS  Google Scholar 

  50. Jeu L, Cheng JW. Pharmacology and therapeutics of ezetimibe, a cholesterol-absorption inhibitor. Clin Ther. 2003;25:2352–2387.

    Article  PubMed  CAS  Google Scholar 

  51. Altamann SW, Davis HR, Zhu LJ, et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303:1201–1204.

    Article  Google Scholar 

  52. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA. 2005;102:8132–8137.

    Article  PubMed  CAS  Google Scholar 

  53. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40:2125–2134.

    Article  PubMed  CAS  Google Scholar 

  54. Yoneda M, Fujita K, Nozaki Y, et al. Efficacy of ezetimibe for the treatment on non-alcoholic steatohepatitis: an open label, pilot study. Hepatol Res. 2010;40:613–621.

    Article  PubMed  Google Scholar 

  55. Chan DC, Watts GF, Gan SK, Ooi EM, Barrett PH. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care. 2010;33:1143–1149.

    Article  Google Scholar 

  56. Park H, Shima T, Yamaguchi K, et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:101–107.

    Article  PubMed  CAS  Google Scholar 

  57. Storlien LH, Kraegen EW, Chisholm DJ, Ford GL, Bruce DG, Pascoe WS. Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science. 1987;237:885–888.

    Article  PubMed  CAS  Google Scholar 

  58. Araya J, Rodrigo R, Videla LA, et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci. 2004;106:635–643.

    Article  PubMed  CAS  Google Scholar 

  59. Yu S, Rao S, Reddy JK. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr Mol Med. 2003;3:561–572.

    Article  PubMed  CAS  Google Scholar 

  60. Flachs P, Mohamed-Ali V, Horakova O, et al. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetelogia. 2006;49:394–397.

    Article  CAS  Google Scholar 

  61. Cappani M, Callela F, Biagini MR, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic staetosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol. 2006;23:1143–1151.

    Article  Google Scholar 

  62. Spadaro L, Magliocco O, Spampinato D, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver diseases. Dig Liver Dis. 2008;40:194–199.

    Article  PubMed  CAS  Google Scholar 

  63. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol. 2007;47:711–717.

    Article  PubMed  CAS  Google Scholar 

  64. Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol. 2008;42:413–418.

    Article  PubMed  CAS  Google Scholar 

  65. Sofi F, Giangrandi I, Cesari F, et al. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid–enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. In J Food Sci Nutr. 2010;61:792–802.

    Article  CAS  Google Scholar 

  66. Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty liver acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol. 2008;14:6395–6400.

    Article  PubMed  CAS  Google Scholar 

  67. Weismantel D, Danis P. Clinical inquiries. What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol lowering agents? J Fam Pract. 2001;50:927–928.

    PubMed  CAS  Google Scholar 

  68. American Gastroenterology Association medical position statement: evaluation of liver chemistry tests. Gastroenterology. 2002;123:1702–1704.

    Google Scholar 

  69. Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation. 2002;123:1702–1704.

    Google Scholar 

  70. Anfossi G, Massucco P, Bonomo K, Trovati M. Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. Nutr Metab Cardiovasc Dis. 2004;14:215–224.

    Article  PubMed  CAS  Google Scholar 

  71. Bhardawaj SS, Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis. 2007;11:597–613.

    Article  Google Scholar 

  72. Tzefos M, Olin JL. 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy. J Clin Lipdol. 2011;5:450–459.

    Article  Google Scholar 

Download references

Acknowledgments

The authors also wish to thank Dr. A. Bomzon, Consulwrite (http://www.consulwrite.com), for his editorial assistance in preparing this review.

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to William Nseir.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nseir, W., Mograbi, J. & Ghali, M. Lipid-Lowering Agents in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Human Studies. Dig Dis Sci 57, 1773–1781 (2012). https://doi.org/10.1007/s10620-012-2118-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-012-2118-3

Keywords

Navigation